MedTrace Logo

CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients

NCT00987792 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2595

Last updated 2015-08-07

No results posted yet for this study

Summary

The aim of this study is to obtain data from hospitalized Community Acquired Pneumonia (CAP) patients on the disease including disease severity, clinical signs and symptoms and measures used for diagnosis in daily routine practice as well as data on Avelox® including information on the use, effectiveness, treatment outcome, safety and tolerability.

As this is a non-interventional observational study, routine clinical practice is observed. The application of medications follows the normal routines and is decided by the treating physician under recognition of the package insert.

Conditions

Interventions

DRUG

Moxifloxacin (Avelox, BAY12-8039)

Hospitalized patients receiving Avelox according to local drug information

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-06-30
Completion
2012-10-31

Countries

  • Croatia
  • France
  • Hungary
  • Jordan
  • Kazakhstan
  • Lebanon
  • Moldova
  • North Macedonia
  • Romania
  • Russia
  • Ukraine

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00987792 on ClinicalTrials.gov